Active piezoelectric bone conduction implant Osia® 2 - evaluation of surgery and one-year audiological and quality of life benefits
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-024-09057-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Wojciech Gawęcki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznań, Poland. wojgaw@interia.pl. Hauptthemen laut MEDLINE: Quality of Life, Bone Conduction, Hearing Loss, Conductive, Hearing Loss, Mixed Conductive-Sensorineural. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To present the surgical outcomes and one-year audiological and quality of life results of implantation of the Osia ® 2 active piezoelectric bone conduction implant.
Methods
Twenty adults with mixed and conductive hearing loss were implanted with the Osia ® 2 system and followed up for at least one year. The surgical course, healing, and soft tissue condition were assessed. Audiometric tests included pure tone audiometry, speech audiometry and direct bone conduction measurements. Participants completed the APHAB and SSQ questionnaires.
Results
All surgeries were successful. No soft tissue problems were observed. Pure tone audiometry showed a mean functional gain of 47.4 ± 5.6 dB HL ( p = 0.000089). The Polish Monosyllabic Word Test showed mean improvements for silent, medium and loud speech of 59.5 ± 1.8%, 46.5 ± 32.3% and 13.3 ± 20.9% in quiet and 38.5 ± 24.4%, 62.0 ± 9.1%, and 36.5 ± 34.4% in noise (all p < 0.05). The Polish Matrix Test indicated a mean SNR improvement of 8.78 ± 2.31 dB SPL ( p = 0.000155). BC in situ measurements were significantly better post-implantation compared to preoperative levels with Baha ® 6 Max on the Softband. APHAB scores showed significant improvements in global, ease of communication, background noise and reverberation scores (all p < 0.001). SSQ scores improved significantly in speech, spatial and quality subscales (all p < 0.000001).
Conclusion
The Osia ® 2 implantation is an effective treatment for patients with mixed and conductive hearing loss. The surgery is relatively easy and safe, with no significant postoperative or magnet pressure-related complications. Osia ® 2 significantly improves speech understanding in noise and reduces communication problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznań, Poland. wojgaw@interia.pl.
- Department of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznań, Poland.
- Medicus sp. z o.o, Wrocław, Poland.
- University of Silesia in Katowice, Katowice, Poland.
- Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland.
- Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.
Zitieren
APA
Gawęcki, W., Gibasiewicz, R., Błaszczyk, M., Wierzbicka, M., & Bartkowiak, E. (2025). Active piezoelectric bone conduction implant Osia® 2 - evaluation of surgery and one-year audiological and quality of life benefits. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-09057-2
Vancouver
Gawęcki W, Gibasiewicz R, Błaszczyk M, Wierzbicka M, Bartkowiak E. Active piezoelectric bone conduction implant Osia® 2 - evaluation of surgery and one-year audiological and quality of life benefits. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-09057-2
BibTeX
@article{Gawcki2025,
author = {Gawęcki, Wojciech and Gibasiewicz, Renata and Błaszczyk, Magdalena and Wierzbicka, Małgorzata and Bartkowiak, Ewelina},
title = {Active piezoelectric bone conduction implant Osia® 2 - evaluation of surgery and one-year audiological and quality of life benefits},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-024-09057-2}
}
EUVIMED